Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy – Markets Insider

TrueBlueTribuneBiogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular AtrophyMarkets InsiderBiogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA …Biogen extends Ionis deal in SMAThe Pharma LetterBiogen, Ionis Ink Deal for Spinal Muscular Atrophy TherapiesNasdaqWith AveXis coming up in the rear view mirror, Biogen and Ionis go back to the drawing board on SMAEndpoints NewsZacks Investment Research -SEC.gov -American Consumer News, LLCall 70 news articles »

Read More

Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy – Business Wire (press release)

Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular AtrophyBusiness Wire (press release)CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)–Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug …and more »

Read More

Progress made toward treatment for rare, fatal neurological disease – University of Wisconsin-Madison

University of Wisconsin-MadisonProgress made toward treatment for rare, fatal neurological diseaseUniversity of Wisconsin-MadisonIn the study, published this month in the Annals of Neurology, researchers introduced short, chemically modified fragments of DNA – called antisense oligonucleotides – into cells in laboratory dishes or directly into the brains of mice with Alexander …

Read More

What Kind of Picture Are the Technicals Painting For Antisense Therapeutics Ltd (ANP.AX)? Shares Tick -7.69% – Clawson News

What Kind of Picture Are the Technicals Painting For Antisense Therapeutics Ltd (ANP.AX)? Shares Tick -7.69%Clawson NewsNeedle moving action has been spotted in Antisense Therapeutics Ltd (ANP.AX) as shares are moving today on volatility -7.69% or $-0.002 from the open. The ASX listed company saw a recent bid of $0.024 and 50226 shares have traded hands in the session …and more »

Read More

Putting Antisense Therapeutics Ltd (ANP.AX) Under the Microscope: Stock Ticks -0.002 – Stock Press Daily

Putting Antisense Therapeutics Ltd (ANP.AX) Under the Microscope: Stock Ticks -0.002Stock Press DailyNeedle moving action has been spotted in Antisense Therapeutics Ltd (ANP.AX) as shares are moving today on volatility -7.69% or $-0.002 from the open. The ASX listed company saw a recent bid of $0.024 and 50226 shares have traded hands in the session …and more »

Read More

Ionis’ License Agreement for Huntington’s Disease Drug, IONIS-HTT … – Markets Insider

Third Force NewsIonis’ License Agreement for Huntington’s Disease Drug, IONIS-HTT …Markets InsiderCARLSBAD, Calif., Dec. 18, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that its license agreement with Roche to develop and commercialize IONIS-HTTRx for the treatment of people with. Huntington’s disease (HD) has …Ionis earns $45M fee from Roche for rights to Huntington’s candidateSeeking Alphaall 4 news articles »

Read More

Splicing: Going in circles – Nature.com

Nature.comSplicing: Going in circlesNature.comThis was confirmed using an antisense oligonucleotide that targeted the intergenic region, which considerably reduced intergenic RNA levels and simultaneously decreased circPAIP2 levels. Thus, circRNA levels increase when the canonical splicing of the …

Read More

Trading Focus: Piotroski F Score Below Five on Shares of Antisense Therapeutics Ltd (ANP.AX) – Hayden Business Journal

Trading Focus: Piotroski F Score Below Five on Shares of Antisense Therapeutics Ltd (ANP.AX)Hayden Business JournalLooking at the numbers for Antisense Therapeutics Ltd (ANP.AX), we can now see that the Piotroski F Score reading is at five or lower. Tracking this signal, investors may be looking for signs of possible financial weakness. The Average Directional …and more »

Read More

Ionis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference – NB Herard

The Lincolnian OnlineIonis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare ConferenceNB HerardCARLSBAD, Calif., Dec. 15, 2017 — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January …Head to Head Analysis: Ionis Pharmaceuticals (NASDAQ:IONS) and Its RivalsWeek Heraldall 13 news articles »

Read More

Ionis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference – GuruFocus.com

The Lincolnian OnlineIonis Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare ConferenceGuruFocus.comIonis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense …Head to Head Analysis: Ionis Pharmaceuticals (NASDAQ:IONS) and …Week Heraldall 15 news articles »

Read More

Antisense Therapy A Promising New Approach To Neurological Disease – ReliaWire

ReliaWireAntisense Therapy A Promising New Approach To Neurological DiseaseReliaWireA new treatment for Huntington’s disease – a deadly brain disorder – has successfully completed first-in-human trials. The drug lowered levels of the harmful huntingtin protein in the spinal fluid of patients who took part in the trial. Huntington’s …Roche licenses IONIS-HTTRX drug for treating Huntington’s diseaseThe Camping Canuck (press release) (blog)all 5 news articles »

Read More

Newly identified THOR gene could play a role in suppressing tumors – FierceBiotech

FierceBiotechNewly identified THOR gene could play a role in suppressing tumorsFierceBiotechThis approach, called antisense oligonucleotides, is already well-known in biotech. Atlantic Healthcare recently started a rolling submission for FDA approval of its antisense drug to treat inflammatory bowel disease, and Ionis recently licensed a …How defeating THOR could bring a hammer down on cancerEurekAlert (press release)all 5 news articles »

Read More

Mechanisms of HERV-K (HML-2) Transcription during Human Mammary Epithelial Cell Transformation – Journal of Virology

Mechanisms of HERV-K (HML-2) Transcription during Human Mammary Epithelial Cell TransformationJournal of VirologyImportantly, LTR-driven transcription was restricted to tumorigenic cells, suggesting that LTR promoter activity is dependent upon the transcriptional environment of a malignant cell. IMPORTANCE Here, we use an in vitro model of human mammary …and more »

Read More

Antisense Oligonucleotide Squelches Huntingtin Protein in Phase 1/2a Trial – Alzforum

Genetic Engineering & Biotechnology NewsAntisense Oligonucleotide Squelches Huntingtin Protein in Phase 1/2a TrialAlzforumAn antisense oligonucleotide knocked down levels of the mutant huntingtin protein in Huntington’s disease patients, who appeared to tolerate treatment well, according to a December 11 announcement by Ionis Pharmaceuticals, Inc., in Carlsbad, California …Incurable Huntington’s disease might finally have a treatmentEconomic TimesRoche Licenses Ionis’ Antisense HD Therapy Following Groundbreaking TrialGenetic Engineering & Biotechnology NewsRoche snaps up Huntington’s drug on positive dataBioPharma DiveMedscapeall 13 news articles »

Read More

Roche Licenses Ionis’ Antisense HD Therapy Following Groundbreaking Trial – Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology NewsRoche Licenses Ionis’ Antisense HD Therapy Following Groundbreaking TrialGenetic Engineering & Biotechnology NewsRoche exercised its option to license Ionis Pharmaceuticals’ Huntington’s disease (HD) antisense drug candidate IONIS-HTTRX on the back of what have been called “groundbreaking” results from a placebo-controlled Phase I/IIa dose-escalation study. Roche …Ionis Pharma licenses IONIS-HTT Rx to Roche following successful phase 1/2a study in patients with Huntington’s …pharmabiz.comRoche Licenses Promising Huntington’s Therapy IONIS-HTTRx, Begins Extension StudyHuntington’s Disease Newsall 3 news articles »

Read More